12.18.20 -- Cytiva's Greatest Hits For Gene Therapy -- 2020 Edition

To meet your demand for high-quality adeno-associated virus (AAV) now and in the future, you need a scalable and cost-effective way to make it. Adapt this efficient process that we developed by optimizing each step from suspension cell culture to purified bulk.

Process scalability, lot-to-lot consistency, and the cost and supply of high-quality plasmid are some of the constraints that have made manufacturing of lentiviral vectors (LVs) challenging. Here, we demonstrate a high-yield LV production process, using animal-derived component-free (ADCF) media and reagents, where multiple or continuous vector harvests could be obtained from a single batch.

Learn how two companies collaborated on a next-generation chromatography resin for the purification of plasmid DNA to reduce development costs and increase the manufacturing capacity through increased plasmid batch size and facility throughput.

Accelerating the production of your viral vector-based therapy requires understanding the strategies and cost-efficiencies available to address the viral vector manufacturing shortage.

Frost & Sullivan recently invited industry leaders with gene therapy experience to participate in a new thought leadership forum. This forum brought together leading minds in this emerging field to discuss key challenges and other insights related to reducing the cost of goods (COGs) for gene therapy.

You have a new biotherapeutic in development that has shown promise in preclinical studies against a life-threatening disease. Affected patients and their providers are anxiously awaiting a new treatment option. How do you get your drug into the clinic quickly? Here, we map out basic information to help you approach regulatory policies and offer helpful strategies to facilitate efficient regulatory review and drug approval.